Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular pathogenesis of diffuse large B-cell lymphoma.

Literature DB >> 21842702

Molecular pathogenesis of diffuse large B-cell lymphoma.

Christof Schneider¹, Laura Pasqualucci, Riccardo Dalla-Favera.

Abstract

In past years, substantial insight regarding the pathogenesis of diffuse large B-cell lymphoma has been obtained. Particularly, based on gene expression profile analysis, this disease can be classified into distinct phenotypic subgroups and specific transcriptional programs have been identified. New technologies like next-generation whole genome/exome sequencing and genome-wide single nucleotide polymorphism array analysis have revealed novel lesions involved in the pathogenesis of this disease. This review focuses on the diversity of genetic lesions identified in the different subtypes of diffuse large B-cell lymphoma.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Year: 2011 PMID： 21842702 PMCID： PMC3562715 DOI： 10.1053/j.semdp.2011.04.001

Source DB: PubMed Journal: Semin Diagn Pathol ISSN： 0740-2570 Impact factor: 3.464

123 in total

1. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

Authors: Lloyd T Lam; R Eric Davis; Jackie Pierce; Michael Hepperle; Yajun Xu; Maria Hottelet; Yuhua Nong; Danyi Wen; Julian Adams; Lenny Dang; Louis M Staudt
Journal: Clin Cancer Res Date: 2005-01-01 Impact factor: 12.531

2. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.

Authors: M H Kramer; J Hermans; E Wijburg; K Philippo; E Geelen; J H van Krieken; D de Jong; E Maartense; E Schuuring; P M Kluin
Journal: Blood Date: 1998-11-01 Impact factor: 22.113

3. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.

Authors: W Gu; R G Roeder
Journal: Cell Date: 1997-08-22 Impact factor: 41.582

4. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma.

Authors: O Monni; H Joensuu; K Franssila; J Klefstrom; K Alitalo; S Knuutila
Journal: Blood Date: 1997-08-01 Impact factor: 22.113

5. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas.

Authors: M Pinyol; F Cobo; S Bea; P Jares; I Nayach; P L Fernandez; E Montserrat; A Cardesa; E Campo
Journal: Blood Date: 1998-04-15 Impact factor: 22.113

6. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation.

Authors: W Chen; S Iida; D C Louie; R Dalla-Favera; R S Chaganti
Journal: Blood Date: 1998-01-15 Impact factor: 22.113

7. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors: Ryan T Phan; Riccardo Dalla-Favera
Journal: Nature Date: 2004-12-02 Impact factor: 49.962

8. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes.

Authors: H M Shen; A Peters; B Baron; X Zhu; U Storb
Journal: Science Date: 1998-06-12 Impact factor: 47.728

9. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor.

Authors: H Niu; B H Ye; R Dalla-Favera
Journal: Genes Dev Date: 1998-07-01 Impact factor: 11.361

10. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci.

Authors: L Pasqualucci; A Migliazza; N Fracchiolla; C William; A Neri; L Baldini; R S Chaganti; U Klein; R Küppers; K Rajewsky; R Dalla-Favera
Journal: Proc Natl Acad Sci U S A Date: 1998-09-29 Impact factor: 11.205

34 in total

Review 1. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors: Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal: Mol Cancer Date: 2015-12-11 Impact factor: 27.401

2. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.

Authors: Zijun Y Xu-Monette; Hongwei Zhang; Feng Zhu; Alexandar Tzankov; Govind Bhagat; Carlo Visco; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; Hua You; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; J Han van Krieken; Miguel A Piris; Jane N Winter; Fredrick B Hagemeister; Babak Shahbaba; Ivan De Dios; Hong Zhang; Yong Li; Bing Xu; Maher Albitar; Ken H Young
Journal: Blood Adv Date: 2020-07-28

3. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.

Authors: Yun Mai; J Jessica Yu; Boris Bartholdy; Zijun Y Xu-Monette; Esther E Knapp; Fei Yuan; Hongshan Chen; B Belinda Ding; Zhihua Yao; Bhaskar Das; Yiyu Zou; Ken He Young; Samir Parekh; B Hilda Ye
Journal: Blood Date: 2016-10-13 Impact factor: 22.113

4. Detection of human JCPyV and BKPyV in diffuse large B-cell lymphoma of the GI tract.

Authors: C E Tseng; C M Yeh; C Y Fang; J Shay; P L Chen; M C Lin; D Chang; M Wang
Journal: Eur J Clin Microbiol Infect Dis Date: 2013-11-21 Impact factor: 3.267

5. Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas.

Authors: Shoukat Afshar-Sterle; Dimitra Zotos; Nicholas J Bernard; Anna K Scherger; Lisa Rödling; Amber E Alsop; Jennifer Walker; Frederick Masson; Gabrielle T Belz; Lynn M Corcoran; Lorraine A O'Reilly; Andreas Strasser; Mark J Smyth; Ricky Johnstone; David M Tarlinton; Stephen L Nutt; Axel Kallies
Journal: Nat Med Date: 2014-02-02 Impact factor: 53.440

Review 6. Genetic lesions in diffuse large B-cell lymphomas.

Authors: M Testoni; E Zucca; K H Young; F Bertoni
Journal: Ann Oncol Date: 2015-01-20 Impact factor: 32.976

7. Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era.

Authors: Lindsay M Morton; Clara J Kim; Lawrence M Weiss; Kishor Bhatia; Myles Cockburn; Debra Hawes; Sophia S Wang; Cindy Chang; Sean F Altekruse; Eric A Engels; Wendy Cozen
Journal: Leuk Lymphoma Date: 2013-07-29